|
|
|
|||
Michael
L. Cher, M.D.
Associate
Professor, Urology and Pathology
Education
Stanford University, Palo Alto, CA: B.S. in Chemistry, 1982
Washington University School of Medicine, St. Louis, MO: M.D., 1986
Medical
Training
General Surgery Residency, University of Texas Southwestern Medical Center,
Dallas, TX, 1986-88.
Urology Residency, University of Texas Southwestern Medical Center, Dallas,
TX, 1988-92.
Fellowship in Urologic Oncology and Molecular Cytogenetics, University of California
School of Medicine, San Francisco, CA, 1992-1995.
Faculty
and Hospital Appointments
Associate Professor, Wayne State University Departments of Urology and Pathology
Member, Karmanos Cancer Institute, Genitourinary Oncology Program
Attending Urologist, Detroit Medical Center Hospitals and Detroit Veteran's
Administration Hospital
Clinical
Interests:
Urologic Oncology, General Adult Urology.
Research
Interests:
Biology of prostate cancer metastasis, genetics of urologic malignancies; characterization
of prostate cancer micrometastases
Selected
Publications:
1. Bianco, F. J., Jr., Wood, D. P., Jr., Gomes de Oliveira, J., Nemeth,
J. A., Beaman, A. A., and Cher, M. L. Proliferation of prostate cancer cells
in the bone marrow predicts recurrence in patients with localized prostate cancer.
Prostate, 49: 235-242, 2001.
2. Bianco, F. J., Jr., Powell,
I. J., Cher, M. L., and Wood, D. P., Jr. Presence of circulating prostate cancer
cells in African American males adversely affects survival. Urol Oncol, 7:
147-152, 2002.
3. Cher, M. L. and Allen,
T. D. Continence in the myelodysplastic patient following enterocystoplasty.
J Urol, 149: 1103-1106, 1993.
4. Cher, M. L., Milchgrub,
S., and Sagalowsky, A. I. Transitional cell carcinoma of the ureteral stump
23 years after radical nephrectomy for adenocarcinoma. J Urol, 149: 106-108,
1993.
5. Cher, M. L., MacGrogan,
D., Bookstein, R., Brown, J. A., Jenkins, R. B., and Jensen, R. H. Comparative
genomic hybridization, allelic imbalance, and fluorescence in situ hybridization
on chromosome 8 in prostate cancer. Genes Chromosomes Cancer, 11: 153-162,
1994.
6. Cher, M. L. and Carroll,
P. R. Screening for prostate cancer. West J Med, 160: 250, 1994.
7. Cher, M. L., Shinohara,
K., Breslin, S., Vapnek, J., and Carroll, P. R. High failure rate associated
with long-term follow-up
of neoadjuvant androgen deprivation followed by radical prostatectomy for stage
C prostatic cancer. Br J Urol, 75: 771-777, 1995.
8. Cher, M. L. and Carroll,
P. R. Screening for prostate cancer. West J Med, 162: 235-242, 1995.
9. Cher, M. L., Chew, K.,
Rosenau, W., and Carroll, P. R. Cellular proliferation in prostatic adenocarcinoma
as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate,
26: 87-93, 1995.
10. Cher, M. L., Ito, T.,
Weidner, N., Carroll, P. R., and Jensen, R. H. Mapping of regions of physical
deletion on chromosome 16q in prostate cancer cells by fluorescence in situ
hybridization (FISH). J Urol, 153: 249-254, 1995.
11. Cher, M. L., Bova, G.
S., Moore, D. H., Small, E. J., Carroll, P. R., Pin, S. S., Epstein, J. I.,
Isaacs, W. B., and Jensen, R. H. Genetic alterations in untreated metastases
and androgen-independent prostate cancer detected by comparative genomic hybridization
and allelotyping. Cancer Res, 56: 3091-3102, 1996.
12. Cher, M. L., Stephenson,
R. A., James, B. C., and Carroll, P. R. Cellular proliferative fraction of metastatic
lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer. J Urol,
155: 1674-1677, 1996.
13. Cher, M. L., Abernathy,
B. B., McConnell, J. D., Zimmern, P. E., and Lin, V. K. Smooth-muscle myosin
heavy-chain isoform expression in bladder-outlet obstruction. World J Urol,
14: 295-300, 1996.
14. Cher, M. L., Bianco,
F. J., Jr., Lam, J. S., Davis, L. P., Grignon, D. J., Sakr, W. A., Banerjee,
M., Pontes, J. E., and Wood, D. P., Jr. Limited role of radionuclide bone scintigraphy
in patients with prostate specific antigen elevations after radical prostatectomy.
J Urol, 160: 1387-1391, 1998.
15. Cher, M. L., Lewis,
P. E., Banerjee, M., Hurley, P. M., Sakr, W., Grignon, D. J., and Powell, I.
J. A similar pattern of chromosomal alterations in prostate cancers from African-Americans
and Caucasian Americans. Clin Cancer Res, 4: 1273-1278, 1998.
16. Cher, M. L., de Oliveira,
J. G., Beaman, A. A., Nemeth, J. A., Hussain, M., and Wood, D. P., Jr. Cellular
proliferation and prevalence of micrometastatic cells in the bone marrow of
patients with clinically localized prostate cancer. Clin Cancer Res, 5:
2421-2425, 1999.
17. Cher, M. L. Mechanisms
governing bone metastasis in prostate cancer. Curr Opin Urol, 11: 483-488,
2001.
18. Cher, M. L., Biliran,
H. R., Jr., Bhagat, S., Meng, Y., Che, M., Lockett, J., Abrams, J., Fridman,
R., Zachareas, M., and Sheng, S. Maspin expression inhibits osteolysis, tumor
growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc
Natl Acad Sci U S A, 100: 7847-7852, 2003.
19. Connolly, J. A., Presti,
J. C., Jr., Cher, M. L., Chew, K., Shinohara, K., and Carroll, P. R. Accelerated
tumor proliferation rates in locally recurrent prostate cancer after radical
prostatectomy. J Urol, 158: 515-518, 1997.
20. Dong, Z., Nemeth, J.
A., Cher, M. L., Palmer, K. C., Bright, R. C., and Fridman, R. Differential
regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1
(TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal
cells. Int J Cancer, 93: 507-515, 2001.
21. Gheiler, E. L., Tefilli,
M. V., Tiguert, R., Grignon, D., Cher, M. L., Sakr, W., Pontes, J. E., and Wood,
D. P., Jr. Predictors for maximal outcome in patients undergoing salvage surgery
for radio-recurrent prostate cancer. Urology, 51: 789-795, 1998.
22. Godfrey, T. E., Cher,
M. L., Chhabra, V., and Jensen, R. H. Allelic imbalance mapping of chromosome
16 shows two regions of common deletion in prostate adenocarcinoma. Cancer Genet
Cytogenet, 98: 36-42, 1997.
23. Hillman, G. G., Triest,
J. A., Cher, M. L., Kocheril, S. V., and Talati, B. R. Prospects of immunotherapy
for the treatment of prostate carcinoma--a review. Cancer Detect Prev, 23:
333-342, 1999.
24. Honn, K. V., Aref, A.,
Chen, Y. Q., Cher, M. L., Crissman, J. D., Forman, J. D., Gao, X., Grignon,
D., Hussain, M., Porter, A. T., Pontes, J. E., Powell, I. I., Redman, B., Sakr,
W., Severson, R., Tang, D. G., and Wood, D. P., Jr. Prostate Cancer Old Problems
and New Approaches. Part III. Prevention and Treatment. Pathol Oncol Res, 2:
276-292, 1996.
25. Honn, K. V., Aref, A.,
Chen, Y. Q., Cher, M. L., Crissman, J. D., Forman, J. D., Gao, X., Grignon,
D., Hussain, M., Porter, A. T., Pontes, E. J., Powell, I. I., Redman, B., Sakr,
W., Severson, R., Tang, D. G., and Wood, D. P., Jr. Prostate Cancer - Old Problems
and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and
Biological Aspects). Pathol Oncol Res, 2: 191-211, 1996.
26. Hukku, B., Mally, M.,
Cher, M. L., Peehl, D. M., Kung, H., and Rhim, J. S. Stepwise genetic changes
associated with progression
of nontumorigenic HPV-18 immortalized human prostate cancer-derived cell line
to a malignant phenotype. Cancer Genet Cytogenet, 120: 117-126, 2000.
27. Kattar, M. M., Grignon,
D. J., Eble, J. N., Hurley, P. M., Lewis, P. E., Sakr, W. E., and Cher, M. L.
Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization:
evidence for clonal origin. Hum Pathol, 30: 295-299, 1999.
28. Mohla, S., Weilbacher,
K. N., Cher, M. L., Oyajobi, B. O., Poznak, C. V., and Clohisy, D. R. Third
North American Symposium on Skeletal Complications of Malignancy: summary of
the scientific sessions. Cancer, 97: 719-725, 2003.
29. Moore, D. H., 2nd, Pallavicini,
M., Cher, M. L., and Gray, J. W. A t-statistic for objective interpretation
of comparative genomic hybridization (CGH) profiles. Cytometry, 28: 183-190,
1997.
30. Mueller, P., Carroll,
P., Bowers, E., Moore, D., 2nd, Cher, M., Presti, J., Wessman, M., and Pallavicini,
M. G. Low frequency epithelial cells in bone marrow aspirates from prostate
carcinoma patients are cytogenetically aberrant. Cancer, 83: 538-546,
1998.
31. Narain, V., Cher, M.
L., and Wood, D. P., Jr. Prostate cancer diagnosis, staging and survival. Cancer
Metastasis Rev, 21: 17-27, 2002.
32. Nemeth, J. A., Harb,
J. F., Barroso, U., Jr., He, Z., Grignon, D. J., and Cher, M. L. Severe combined
immunodeficient-hu model of human prostate cancer metastasis to human bone.
Cancer Res, 59: 1987-1993, 1999.
33. Nemeth, J. A., Roberts,
J. W., Mullins, C. M., and Cher, M. L. Persistence of human vascular endothelium
in experimental human prostate cancer bone tumors. Clin Exp Metastasis, 18:
231-237, 2000.
34. Nemeth, J. A., Yousif,
R., Herzog, M., Che, M., Upadhyay, J., Shekarriz, B., Bhagat, S., Mullins, C.,
Fridman, R., and Cher, M. L. Matrix metalloproteinase activity, bone matrix
turnover, and tumor cell proliferation in prostate cancer bone metastasis. J
Natl Cancer Inst, 94: 17-25, 2002.
35. Powell, I. J., Dey,
J., Dudley, A., Pontes, J. E., Cher, M. L., Sakr, W., Grignon, D. J., and Wood,
D. P. Disease-free survival difference between African Americans and whites
after radical prostatectomy for local prostate cancer: a multivariable analysis.
Urology, 59: 907-912, 2002.
36. Toth, M., Bernardo,
M. M., Gervasi, D. C., Soloway, P. D., Wang, Z., Bigg, H. F., Overall, C. M.,
DeClerck, Y. A., Tschesche, H., Cher, M. L., Brown, S., Mobashery, S., and Fridman,
R. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with
synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance
the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem, 275:
41415-41423, 2000.
37. Triest, J. A., Grignon,
D. J., Cher, M. L., Kocheril, S. V., Montecillo, E. J., Talati, B., Tekyi-Mensah,
S., Pontes, J. E., and Hillman, G. G. Systemic interleukin 2 therapy for human
prostate tumors in a nude mouse model. Clin Cancer Res, 4: 2009-2014,
1998.
38. Upadhyay, J., Shekarriz,
B., Nemeth, J. A., Dong, Z., Cummings, G. D., Fridman, R., Sakr, W., Grignon,
D. J., and Cher, M. L. Membrane type 1-matrix metalloproteinase (MT1-MMP) and
MMP-2 immunolocalization in human prostate: change in cellular localization
associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer
Res, 5: 4105-4110, 1999.
39. Virgin, J. B., Hurley,
P. M., Nahhas, F. A., Bebchuk, K. G., Mohamed, A. N., Sakr, W. A., Bright, R.
K., and Cher, M. L. Isochromosome 8q formation is associated with 8p loss of
heterozygosity in a prostate cancer cell line. Prostate,41:
49-57, 1999.
40. Wolf, J. S., Jr., Cher,
M., Dall'era, M., Presti, J. C., Jr., Hricak, H., and Carroll, P. R. The use
and accuracy of cross-sectional imaging and fine needle aspiration cytology
for detection of pelvic lymph node metastases before radical prostatectomy.
J Urol, 153: 993-999, 1995.
41. Wood, D. P., Jr., Beaman,
A., Banerjee, M., Powell, I., Pontes, E., and Cher, M. L. Effect of neoadjuvant
androgen deprivation on circulating prostate cells in the bone marrow of men
undergoing radical prostatectomy. Clin Cancer Res, 4: 2119-2123, 1998.
42. Yeatman, T. J., Cher, M. L., Mao, W., Wloch, M., and Tedesco, T. Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse. Clin Exp Metastasis, 14: 246-252, 1996.
Office Address: Department
of Pathology and Urology
Wayne State University
Scott Hall Room 9112
Detroit, MI 48201
e-mail: mcher@med.wayne.edu